Payment overview · 2025
General Payments
$1,214.25
20 reported records · 8 companies
Healthcare provider profile · identity verified
Alba Gutierrez, PAC
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · BRAWLEY, CA · NPI 1972548535
Verified facts
What the public records show
CMS Open Payments records show Alba Gutierrez, PAC received $1,214.25 in general payments during 2025 across 20 reported records.
AstraZeneca Pharmaceuticals LP accounted for 32.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $390.24 | 32.1% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $257.69 | 21.2% | 5 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $142.84 | 11.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $138.41 | 11.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $125.00 | 10.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $99.96 | 8.2% | 4 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $35.01 | 2.9% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $25.10 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,214.25 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $264.49 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $227.36 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $215.76 | 2 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $142.84 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $90.01 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $83.86 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $49.70 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $35.01 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $25.10 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $13.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 127 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 36 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
55 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
127 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
36 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
88 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
213 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 561 | 197 |
| Amlodipine Besylate | Amlodipine Besylate | 380 | 140 |
| Alendronate Sodium | Alendronate Sodium | 367 | 115 |
| Metformin Hcl | Metformin Hcl | 359 | 117 |
| Losartan Potassium | Losartan Potassium | 356 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 317 | 85 |
| Gabapentin | Gabapentin | 254 | 99 |
| Omeprazole | Omeprazole | 236 | 97 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 221 | 122 |
| Ozempic | Semaglutide | 213 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 209 | 105 |
| Escitalopram Oxalate | Escitalopram Oxalate | 205 | 66 |
| Lisinopril | Lisinopril | 183 | 71 |
| Furosemide | Furosemide | 178 | 61 |
| Meloxicam | Meloxicam | 171 | 76 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 169 | 137 |
| Metoprolol Succinate | Metoprolol Succinate | 136 | 50 |
| Simvastatin | Simvastatin | 130 | 40 |
| Farxiga | Dapagliflozin Propanediol | 127 | 27 |
| Sertraline Hcl | Sertraline Hcl | 123 | 36 |
| Montelukast Sodium | Montelukast Sodium | 121 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 39 |
| Trazodone Hcl | Trazodone Hcl | 109 | 44 |
| Paroxetine Hcl | Paroxetine Hcl | 106 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 102 | 33 |
| Ibuprofen | Ibuprofen | 97 | 39 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 96 | 88 |
| Dicyclomine Hcl | Dicyclomine Hcl | 94 | 35 |
| Baclofen | Baclofen | 92 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 27 |
| Jardiance | Empagliflozin | 88 | 20 |
| Prednisone | Prednisone | 83 | 67 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 80 | 61 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 21 |
| Potassium Chloride | Potassium Chloride | 78 | 33 |
| Tramadol Hcl | Tramadol Hcl | 78 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 76 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 75 | 29 |
| Glimepiride | Glimepiride | 74 | 25 |
| Tradjenta | Linagliptin | 73 | 14 |
| Allopurinol | Allopurinol | 71 | 17 |
| Nifedipine Er | Nifedipine | 71 | 21 |
| Januvia | Sitagliptin Phosphate | 69 | 15 |
| Glipizide | Glipizide | 68 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 65 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 62 | 41 |
| Nystatin | Nystatin | 61 | 44 |
| Doxycycline Hyclate | Doxycycline Hyclate | 60 | 55 |
| Meclizine Hcl | Meclizine Hcl | 60 | 40 |
| Dexamethasone | Dexamethasone | 59 | 53 |
| Benazepril Hcl | Benazepril Hcl | 58 | 15 |
| Famotidine | Famotidine | 58 | 17 |
| Linzess | Linaclotide | 55 | 17 |
| Solifenacin Succinate | Solifenacin Succinate | 55 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 22 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 51 | 14 |
| Memantine Hcl | Memantine Hcl | 50 | 17 |
| Carvedilol | Carvedilol | 48 | 16 |
| Azithromycin | Azithromycin | 47 | 47 |
| Celecoxib | Celecoxib | 46 | 16 |
| Entresto | Sacubitril/Valsartan | 46 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 45 | 45 |
| Quetiapine Fumarate | Quetiapine Fumarate | 45 | 13 |
| Cephalexin | Cephalexin | 43 | 39 |
| Naproxen | Naproxen | 42 | 19 |
| Eliquis | Apixaban | 41 | 15 |
| Pentoxifylline | Pentoxifylline | 41 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | 11 |
| Estradiol | Estradiol | 38 | 19 |
| Fenofibrate | Fenofibrate,micronized | 38 | 11 |
| Ketoconazole | Ketoconazole | 38 | 31 |
| Sucralfate | Sucralfate | 36 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | suppressed |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 33 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | 12 |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Lorazepam | Lorazepam | 32 | 11 |
| Megestrol Acetate | Megestrol Acetate | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | 14 |
| Bumetanide | Bumetanide | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | 11 |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Creon | Lipase/Protease/Amylase | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Procto-Med Hc | Hydrocortisone | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Tobramycin | Tobramycin | 19 | 13 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 13 |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Ofloxacin | Ofloxacin | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Veo Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Bystolic | Nebivolol Hcl | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,214.25 · 20 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, AREXVY, BREZTRI, CeQur Simplicity, FARXIGA, KISUNLA, SHINGRIX, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, Wegovy, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error